| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
IoTecha is an industry leader in EV Charging Technology & Vehicle Grid Integration (VGI) Cloud Based Solutions including chargers , software and Vehicle-to-Grid bidirectional charging (V2G).
Scio Management Solutions, headquartered in Sarasota, Florida, is a revenue cycle management company dedicated to delivering superior results for its clients. In addition to revenue cycle management, Scio offers auditing solutions, insurance pre-check,...
axcess.io is a cloud native AWS Consulting Partner and AWS Cloud Computing Service provider. We provide next-gen Cloud Solutions to simplify...